Citywire for Financial Professionals
Share this page:
Stay connected:


Citywire printed articles sponsored by:

View the rest of this gallery online at

The Expert View: Lloyds, AstraZeneca and Sports Direct

Our daily roundup of the best analyst commentary on shares, also including Rathbone Brothers and Aberdeen Asset Management.

by Daniel Grote on Apr 02, 2014 at 05:01

If you’d like to receive news alerts on any of the stocks mentioned in The Expert View, click on the star icons below to add them to your favourites.
Key stats
Market capitalisation£55,121m
No. of shares out71,451m
No. of shares floating47,821m
No. of common shareholdersnot stated
No. of employees88977
Trading volume (10 day avg.)226m
Profit before tax£-838m
Earnings per share-1.18p
Cashflow per share1.60p
Cash per share69.86p

*Correct as at 1 Apr 2014

Lloyds slump presents buying opportunity

The recent slump in Lloyds shares has prompted Numis to upgrade the bank from ‘add’ to ‘buy’.

Lloyds Banking Group shares dropped nearly 10% in March, as the government sold £4.2 billion of shares, bringing down its stake to less than a quarter of the bank. Yesterday Lloyds gained 1.3p to 76p.

Numis analyst Mike Trippitt said the falls had provided for a 30% upside to his 97p target price. He is forecasting 2.2% of capital generation in 2014 and 2015, roughly in line with guidance from management of around 2.5%.

Trippitt added that conduct fines remained the principle investment risk for Lloyds. Lloyds made a further £1.8 billion provision for payment protection insurance redress in the last quarter of last year, taking its 2013 provision to around £3 billion and its total provision to £9.8 billion.

Key stats
Market capitalisation£50,313m
No. of shares out1,261m
No. of shares floating1,258m
No. of common shareholdersnot stated
No. of employees51700
Trading volume (10 day avg.)2m
Turnover15,431m USD
Profit before tax1,534m USD
Earnings per share1.22 USD
Cashflow per share2.60 USD
Cash per share4.78 USD

*Correct as at 1 Apr 2014

Stamp of approval to boost AstraZeneca

Panmure Gordon has upgraded AstraZeneca from ‘sell’ to ‘hold’, after US rival Pfizer gained approval for its over-the-counter version of drug Nexium.

Pfizer paid $250 million in 2012 for the rights to market the non-prescription version of AstraZeneca’s Nexium drug. AstraZeneca will also receive milestone and royalty payments from sales.

Panmure analyst Savvas Neophytou said the approval and the upcoming medical conference season had prompted the upgrade for AstraZeneca.

‘The company has an economic benefit from the new product which we do not see as a direct competitor to prescription Nexium in the US,’ he said.

Neophytou added that non-prescription Nexium was likely to have a bigger impact for AstraZeneca when it is rolled out in European markets in the second half of the year.

Panmure has upped its target price for the stock from £35.00 to £39.00. Yesterday AstraZeneca gained 51p to reach £39.27.

Key stats
Market capitalisation£877m
No. of shares out46m
No. of shares floating44m
No. of common shareholdersnot stated
No. of employees821
Trading volume (10 day avg.)0m
Profit before tax£35m
Earnings per share75.55p
Cashflow per share98.56p
Cash per share456.35p

*Correct as at 1 Apr 2014

Rathbones boost from double swoop

Rathbone Brothers’ announcement of a double acquisition has prompted Peel Hunt to up its target price for the wealth manager from £18.00 to £20.00.

Rathbones has bought Jupiter Asset Management’s private client and charity arms, as well as part of Tilney Investment Management’s London private client business.

Analyst Stuart Duncan reiterated his ‘buy’ rating and said the deals, which swell Rathbones’ assets by around £2.8 billion, would enhance the company’s earnings by 10% in 2015.

‘Overall, the deals look to have been completed at attractive prices, make good sense culturally and strategically, and enhance the investment case,' he said.

Shares in Rathbones yesterday rose 71p to reach £18.85.

Key stats
Market capitalisation£4,988m
No. of shares out1,200m
No. of shares floating851m
No. of common shareholdersnot stated
No. of employees2062
Trading volume (10 day avg.)6m
Profit before tax£308m
Earnings per share26.22p
Cashflow per share34.21p
Cash per share44.56p

*Correct as at 1 Apr 2014

Aberdeen still a ‘buy’ despite outflows

Espirito Santo has reiterated its ‘buy’ rating for Aberdeen Asset Management despite the fund group announcing net outflows of £3.6 billion from its equities business for January and February in a trading update yesterday.

Analyst Phil Dobbin pointed to the net outflows of just £200 million for the whole business over that period, and said he understood outflows from Aberdeen’s emerging market and global funds had not deteriorated in March. He has maintained a target price of 514p.

Aberdeen yesterday announced it had completed its deal to buy fund group Scottish Widows Investment Partnership from Lloyds Banking Group, and revealed wider cost-cutting measures than expected. It gained 34.7p to reach 425p.

Key stats
Market capitalisation£5,317m
No. of shares out598m
No. of shares floating218m
No. of common shareholdersnot stated
No. of employees14076
Trading volume (10 day avg.)2m
Profit before tax£152m
Earnings per share24.42p
Cashflow per share32.90p
Cash per share24.63p

*Correct as at 1 Apr 2014

Buying spree mapped out for Sports Direct

Liberum has raised its target price for Sports Direct from 850p to 950p and reiterated its ‘buy’ rating after identifying potential overseas acquisitions to boost its European presence.

Analyst Sanjay Vidyarthi said that while the company had a presence in 19 European markets, it had limited scale in many of them. ‘Organic growth alone is unlikely to be a viable option to scale, given the concentration of market share with the top three in many markets. Nonetheless, we see sufficient opportunities such that Sports Direct could have a pipeline of one or two meaningful acquisitions a year.’

Sports Direct, founded by Newcastle United owner Mike Ashley, was yesterday up 38.5p at 890.5p.

More about this:

Look up the shares

  • Lloyds Banking Group PLC (LLOY.L)
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • AstraZeneca PLC (AZN.L)
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Rathbone Brothers PLC (RAT.L)
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Aberdeen Asset Management PLC (ADN.L)
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Sports Direct International PLC (SPD.L)
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them


More galleries

 See all

leave a comment

Please sign in here or register here to comment. It is free to register and only takes a minute or two.

Sorry, this link is not
quite ready yet